NAUT on Nasdaq

Nautilus Biotechnology, Inc.

Laboratory analytical instruments company, listed on Nasdaq (NAUT). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerNAUT on Nasdaq1
  • IndustryLaboratory Analytical Instruments1
  • HeadquartersSeattle, Washington1
  • Business address2701 Eastlake Ave East, Seattle, Wa 981022
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”). The Business Combination Agreement provided for, among other things, (i) the domestication of ARYA as a corporation incorporated under the laws of the State of Delaware, upon which ARYA changed its name to “Nautilus Biotechnology, Inc.” (together with its consolidated subsidiary, the “Company” “New Nautilus” or “Nau…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Net income45678-$59.0M in 2025+278% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$15.6M-$15.6M20202021: -$50.3M-$50.3M2021+222%2022: -$57.9M-$57.9M2022+15%2023: -$63.7M-$63.7M2023+10%2024: -$70.8M-$70.8M2024+11%2025: -$59.0M-$59.0M2025−17%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development$41.1M$50.5M
General and administrative$25.7M$31.0M
Total operating expenses$66.8M$81.5M
Interest income$7.9M$10.8M
Other expense-$32.0K-$84.0K
Total other income$7.8M$10.7M
Net loss-$59.0M-$70.8M
Net loss per share attributable to common stockholders, basic (in dollars per share)-$0.47-$0.56
Net loss per share attributable to common stockholders, diluted (in dollars per share)-$0.47-$0.56
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)126.3M shares125.4M shares
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)126.3M shares125.4M shares

Compare Nautilus Biotechnology, Inc. with another company

Leadership

Who has led Nautilus Biotechnology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Adam Leo Stone2020
  2. Sujal M. Patel2021–now

President

  1. Sujal M. Patel2021–now

Chief financial officer

  1. Michael Seth Altman2020
  2. Anna Mowry2021–now
2025
Board members and other officers (20)

Former names

  • ARYA Sciences Acquisition Corp IIIApr 17, 2020 to Jun 8, 20212

Timeline

  1. Jun 9, 2021New chief executive Sujal M. Patel becomes CEO11
  2. Aug 6, 2020New chief executive Adam Leo Stone becomes CEO12

Filings

229 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 33 major events, 109 insider forms, 17 large holders, 50 other. The latest 20:

  1. Sep 18, 2026EFFECT EDGAR
  2. Sep 18, 2026424B5 EDGAR
  3. Sep 11, 20268-K EDGAR
  4. Sep 11, 2026S-3 EDGAR
  5. Sep 11, 2026SCHEDULE 13D/A EDGAR
  6. Aug 28, 2026SCHEDULE 13D/A EDGAR
  7. Aug 14, 2026SCHEDULE 13D/A EDGAR
  8. Jul 28, 202610-Q EDGAR
  9. Jul 28, 20268-K EDGAR
  10. Jun 30, 2026SCHEDULE 13D/A EDGAR
  11. Jun 22, 20264 EDGAR
  12. Jun 22, 20264 EDGAR
  13. Jun 22, 20264 EDGAR
  14. Jun 22, 20264 EDGAR
  15. Jun 22, 20264 EDGAR
  16. Jun 18, 20268-K EDGAR
  17. Jun 4, 2026SCHEDULE 13D/A EDGAR
  18. Jun 4, 20264 EDGAR
  19. Apr 28, 2026ARS EDGAR
  20. Apr 28, 2026DEFA14A EDGAR

The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

38 open-market trades by officers, directors and large owners since October 2021: 35 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2026AH Bio Fund II, L.P.10% ownerSale5,000,000$2.35$11.8MForm 4
Mar 4, 2026Patel Sujal MCEO, President, and SecretaryBuy25,000$2.61$65.2KForm 4
Nov 6, 2025Suzuki KentaroChief Marketing OfficerBuy4,000$1.49$6.0KForm 4
Sep 8, 2025Patel Sujal MCEO, President, and SecretaryBuy83,500$0.68$56.8KForm 4
Sep 5, 2025Patel Sujal MCEO, President, and SecretaryBuy116,500$0.67$78.1KForm 4
Sep 4, 2025Murphy Matthew B.General CounselBuy20,000$0.64$12.8KForm 4
May 29, 2025Mowry AnnaCFO and TreasurerBuy15,000$0.77$11.6KForm 4
May 12, 2025Mallick ParagChief ScientistBuy1,500$0.73$1.1KForm 4
May 8, 2025Mallick ParagChief ScientistBuy12,000$0.73$8.8KForm 4
Mar 20, 2025Patel Sujal MCEO, President, and SecretaryBuy23,933$1.00$23.9KForm 4
Mar 19, 2025Patel Sujal MCEO, President, and SecretaryBuy53,300$0.99$52.8KForm 4
Sep 23, 2024Godwin Mary E.Senior VP, OperationsSale47,031$2.87$135.0KForm 4
Sep 17, 2024Godwin Mary E.Senior VP, OperationsSale35,000$2.85$99.8KForm 4
Mar 11, 2024Patel Sujal MCEO, President, and SecretaryBuy12,044$2.84$34.2KForm 4
Mar 8, 2024Patel Sujal MCEO, President, and SecretaryBuy2,430$2.99$7.3KForm 4
Mar 7, 2024Patel Sujal MCEO, President, and SecretaryBuy18,854$2.89$54.5KForm 4
Mar 6, 2024Patel Sujal MCEO, President, and SecretaryBuy9,267$2.70$25.0KForm 4
Mar 5, 2024Patel Sujal MCEO, President, and SecretaryBuy7,405$2.65$19.6KForm 4
Sep 27, 2022Sankar SubramanianSenior VP, Product DevelopmentBuy5,000$2.03$10.2KForm 4
Sep 26, 2022Sankar SubramanianSenior VP, Product DevelopmentBuy10,000$2.03$20.3KForm 4

All 38 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 91. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Perceptive Advisors LLC11,634,211$21.8M0.3%−960,000
a16z Capital Management, L.L.C.9,063,054$16.9M0.1%−8,590,863
Cercano Management LLC7,172,985$13.4M1.8%No change
BlackRock, Inc.2,687,226$5.0M0.0%+2,499,555
Vanguard Capital Management LLC2,549,979$4.8M0.0%+4,382
Comprehensive Financial Management LLC2,207,619$4.1M0.1%No change
Citadel Advisors LLC1,896,192$3.5M0.0%New
Geode Capital Management, LLC1,265,535$2.4M0.0%+662,011
Clearstead Advisors, LLC892,787$1.7M0.0%−1,436,997
Susquehanna International Group, Llp890,949$1.7M0.0%New
Barclays PLC725,321$1.4M0.0%+651,996
Renaissance Technologies LLC690,514$1.3M0.0%+424,814
Jpmorgan Chase & Co614,177$1.1M0.0%New
State Street Corp559,508$1.0M0.0%+343,238
Dimensional Fund Advisors LP475,844$889.3K0.0%+146,721
Northern Trust Corp381,234$712.9K0.0%+274,223
Vanguard Fiduciary Trust Co353,093$660.3K0.0%+47,567
Vanguard Portfolio Management LLC337,748$631.6K0.0%New
Marshall Wace, Llp265,582$496.6K0.0%−54,300
Qube Research & Technologies Ltd257,346$481.2K0.0%+177,723
Goldman Sachs Group Inc252,751$472.6K0.0%−138,017
Hillman Co200,000$374.0K0.1%No change
Millennium Management LLC188,730$352.9K0.0%−1,084,653
Bridgeway Capital Management, LLC180,000$336.6K0.0%+50,000
Corient Private Wealth LP164,788$308.2K0.0%+50,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37